Companion Animal Osteoarthritis Market Size Worth USD 18.45 Billion by 2034 | CAGR: 23.4%

The companion animal osteoarthritis market size is expected to reach USD 18.45 billion by 2034, according to a new study by Polaris Market Research. The report “Companion Animal Osteoarthritis Market Size, Share, Trend, Industry Analysis Report By Animal (Canine, Equine, Feline), By Product, By Route of Administration, By End Use, By Region – Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The companion animal osteoarthritis market addresses the growing demand for medical solutions targeting degenerative joint conditions in pets, particularly dogs and cats. Osteoarthritis, a chronic and progressive disease, is a leading cause of mobility loss and pain in aging animals. The market is gaining momentum due to increasing awareness among pet owners, a rise in veterinary consultations, and improved diagnostic capabilities. Growth is supported by advancements in pharmaceutical formulations, including long-acting injectable and anti-inflammatory medications that enhance treatment compliance and quality of life for pets.

Do you have any questions? Would you like to request a sample or make an inquiry before purchasing this report? Simply click the link below: https://www.polarismarketresearch.com/industry-analysis/companion-animal-osteoarthritis-market/request-for-sample

Veterinarians are integrating regenerative therapies such as platelet-rich plasma (PRP) and stem cell applications to manage inflammation and promote joint repair. Increasing emphasis on early intervention and multimodal pain management is influencing the development of combination therapies involving drugs, dietary supplements, and physical rehabilitation. Market participants are responding to demand for noninvasive options and breed-specific solutions that address varying risk profiles. Digital tools for monitoring activity levels and mobility are emerging as supportive technologies, enabling better treatment tracking and caregiver engagement. Opportunities continue to grow in preventive care, particularly in the development of joint health supplements and wellness plans for senior pets. The rising trend of pet humanization is pushing manufacturers to prioritize safety, palatability, and evidence-based efficacy. Evolving veterinary guidelines and collaboration between veterinary practices and pharmaceutical companies are driving product innovation and clinical adoption.

Top of FormCompanion Animal Osteoarthritis Market Report Highlights

• By product, the biologics segment accounted for ~54% of the revenue share in 2024 due to their ability to target the underlying causes of osteoarthritis rather than just alleviating symptoms.
• Based on animal, the canine segment held the largest revenue share in 2024 due to the high incidence of osteoarthritis, particularly in aging and large-breed animals.
• In 2024, North America accounted for the largest revenue share due to high pet healthcare spending, advanced veterinary infrastructure, and strong awareness of chronic joint conditions in companion animals.
• The Asia Pacific companion animal osteoarthritis market is expected to grow significantly from 2025 to 2034 due to rising pet adoption, expanding middle-class income, and increasing awareness of animal health.
• A few global key players include Boehringer Ingelheim International GmbH, Ceva, Dechra Pharmaceuticals PLC., Elanco, Eltech K-Laser s.r.l., NexGen Pharmaceuticals, Norbrook, Vetoquinol, Virbac, and Zoetis.

Polaris Market Research has segmented the companion animal osteoarthritis market report on the basis of product, animal, route of administration, end use, and region:

By Product Outlook (Revenue, USD Billion, 2020–2034)

• Biologics
  • Stem Cells
  • Platelet-Rich Plasma (PRP)
  • Monoclonal Antibodies (mAb)
  • Other Biologics
• Viscosupplements
• Pharmaceuticals
  • Steroids
  • NSAIDS
  • Others
• Nutritional Supplements

By Animal Outlook (Revenue, USD Billion, 2020–2034)

• Canine
• Equine
• Feline

By Route of Administration Outlook (Revenue, USD Billion, 2020–2034)

• Oral
• Injectable
• Others

By End Use Outlook (Revenue, USD Billion, 2020–2034)

• Veterinary Hospitals/Clinics
• E-commerce
• Others

By Regional Outlook (Revenue, USD Billion, 2020–2034)

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Vietnam
  • Australia
  • Rest of Asia Pacific
• Latin America
  • Argentina
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa
  • Rest of Middle East & Africa